In September 2025, Imexpharm’s pre-tax profit surged by 101%, while EBITDA grew by 48%. For the first nine months of 2025, the company recorded gross revenue of VND 2,118 billion and net revenue of VND 1,800 billion, marking increases of 21% and 16%, respectively.